Skip to main content

Table 1 Characteristics of the overall cohort

From: Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience

 

Patients (n = 132)

Age, years

58 [47–63]

Male sex

87 (65.9)

Race

 Black

33 (25.0)

 White

95 (72.0)

 Other

4 (3.0)

Hematologic diagnosis

 Multiple myeloma

32 (24.2)

 Myelodysplastic syndrome

9 (6.8)

 Myelofibrosis

9 (6.8)

 Acute myeloid leukemia

27 (20.5)

 Acute lymphatic leukemia

11 (8.3)

 Chronic myeloid leukemia

3 (2.3)

 Chronic lymphatic leukemia

2 (1.5)

 Hodgkin’s lymphoma

8 (6.1)

 Non-Hodgkin’s lymphoma

20 (15.2)

 Aplastic anemia

4 (3.0)

 Other

7 (5.4)

Donor status

 Related

28 (21.2)

 Unrelated

55 (41.7)

 Not applicable

49 (37.1)

HCT type

 Autologous

49 (37.1)

 Allogenic

83 (62.9)

Cardiovascular diseases and risk factors

 Hypertension

71 (53.8)

 Smoking

3 (2.3)

 Diabetes mellitus

20 (15.2)

 Hypercholesterolemia

35 (26.5)

 Chronic kidney disease

4 (3.0)

 CAD

14 (10.3)

 Heart failure

28 (21.2)

 Atrial fibrillation

33 (25.0)

 Pericarditis

6 (4.5)

 None

25 (18.9)

Anti-hypertensive drugs prior to HCT

 b-blockers

68 (51.5)

 Calcium-channel blockers

29 (22.0)

 ACE inhibitors

16 (12.1)

 ARBs

6 (4.5)

 Furosemide/Torsemide

21 (15.9)

 Spironolactone

8 (6.1)

 None

92 (69.7)

Orthostatic Intolerance Syndromes

47 (34.6)

 Orthostatic hypotension pre-HCT

3 (2.3)

 Orthostatic hypotension post-HCT

30 (22.7)

 Tachycardia syndrome

12 (9.1)

  1. The data are presented as a number and (%) of all cases or as median and [interquartile range]
  2. Abbreviations: ACE Angiotensin-converting enzyme, ARBs Angiotensin II receptor blockers, CAD Coronary artery disease, HCT Hematopoietic cell transplantation